The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan).

We assessed the prevalence and incidence of Systemic Lupus Erythematosus (SLE) in 2010 in adults from four cities in Russia, Kazakhstan and Ukraine. Individuals with SLE were identified retrospectively from the medical records of specialized centers. Prevalent SLE patients were nondeceased city residents, diagnosed prior to December 31, 2010; incident patients were residents newly diagnosed between January 1 and December 31, 2010. Population size was obtained from official census data. The observed prevalence rates (per 100,000, 95% CI) were 9.0 (7.1-11.2) in Kursk and Yaroslavl, Russian Federation; 20.6 (15.4-27.0) in Semey, Kazakhstan; and 14.9 (10.9-19.9) in Vinnitsa, Ukraine. The cumulative incidence rates (per 100,000, 95% CI) were 1.4 (0.7-2.4); 1.6 (0.4-4.1) and 0.3 (0.0-1.8), correspondingly. All rates were higher among females compared to males, and incidence peaked in the population aged 25-44. These rates appear slightly lower than those reported from Western Europe and the USA. This could be because of study design (case-ascertainment), local health care practices or true differences in disease risk. Case age and sex distribution was similar to the known epidemiology of SLE. The rates were highest in Kazakhstan, likely because of a predominantly ethnic Asian population.

[Heterogeneity of immunoreactive prolactin in hyperprolactinemia of various origin]. / Geterogennost' immunoreaktivnogo prolaktina pri giperprolaktinemii razlichnogo geneza.

Study of molecular heterogeneity of immunoreactive prolactin in patients with macro- and microprolactinomas and idiopathic hyperprolactinemia has shown heterogeneity of the total blood immunoreactive prolactin pool in all the examined patients. This pool included three basic forms with molecular masses about 23, 50, and over 100 kD (23K-, 50K-, 100K-prolactin), whose ratios essentially differed in individual patients. Physiologically the most active monomeric 23K form of prolactin predominated in the blood of patients with hyperprolactinemia due to hypophyseal micro- and macroadenomas, parallelled by manifest signs of galactorrhea and hypogonadism; the content of this form may reach 95% of the total immunoreactive hormone. Patients with hyperprolactinemia of obscure origin present with quite the contrary ratio of prolactin immunoreactive forms with the predominance of high-molecular 100K form of the hormone, whose share may reach 80-90%. Such cases of hyperprolactinemia may be associated with the absence of clear-cut clinical manifestations, including such as galactorrhea and menstrual cycle disorders, and with inefficacy of traditional therapy. Such cases were tentatively classified as 'the high-molecular prolactin syndrome' and need further research.